XML 107 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2025 and 2024 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment
Three Months Ended September 30, 2025 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 4,935,000 |  |  | $ | 7,000 |  |  | $ | - |  |  | $ | 11,000 |  |  | $ | 1,439,000 |  |  | $ | - |  |  | $ | 6,392,000 |
Cost of revenue |  |  | 4,380,000 |  |  |  | (192,000 | ) |  |  | - |  |  |  | 12,000 |  |  |  | 1,868,000 |  |  |  | - |  |  |  | 6,068,000 |
Gross profit (loss) |  |  | 555,000 |  |  |  | 199,000 |  |  |  | - |  |  |  | (1,000 | ) |  |  | (429,000 | ) |  |  | - |  |  |  | 324,000 |
Operating expense |  |  | 894,000 |  |  |  | 57,000 |  |  |  | (7,587,000 | ) |  |  | 883,000 |  |  |  | (1,754,000 | ) |  |  | 11,065,000 |  |  |  | 3,558,000 |
Operating income (loss) |  |  | (339,000 | ) |  |  | 142,000 |  |  |  | 7,587,000 |  |  |  | (884,000 | ) |  |  | 1,325,000 |  |  |  | (11,065,000 | ) |  |  | (3,234,000 | )
Other income (expense) |  |  | (35,000 | ) |  |  | 370,000 |  |  |  | (21,000 | ) |  |  | 3,000 |  |  |  | 609,000 |  |  |  | 79,000 |  |  |  | 1,005,000 |
Net income (loss) from operations before taxes |  |  | (374,000 | ) |  |  | 512,000 |  |  |  | 7,566,000 |  |  |  | (881,000 | ) |  |  | 1,934,000 |  |  |  | (10,986,000 | ) |  |  | (2,229,000 | )
Three Months Ended September 30, 2024 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 4,846,000 |  |  | $ | 45,000 |  |  | $ | - |  |  | $ | 1,000 |  |  | $ | 707,000 |  |  | $ | - |  |  | $ | 5,599,000 |
Cost of revenue |  |  | 4,350,000 |  |  |  | 252,000 |  |  |  | (2,000 | ) |  |  | 10,000 |  |  |  | 1,993,000 |  |  |  | - |  |  |  | 6,603,000 |
Gross profit (loss) |  |  | 496,000 |  |  |  | (207,000 | ) |  |  | 2,000 |  |  |  | (9,000 | ) |  |  | (1,286,000 | ) |  |  | - |  |  |  | (1,004,000 | )
Operating expense |  |  | 766,000 |  |  |  | 104,000 |  |  |  | 73,000 |  |  |  | 1,169,000 |  |  |  | 901,000 |  |  |  | 654,000 |  |  |  | 3,667,000 |
Operating income (loss) |  |  | (270,000 | ) |  |  | (311,000 | ) |  |  | (71,000 | ) |  |  | (1,178,000 | ) |  |  | (2,187,000 | ) |  |  | (654,000 | ) |  |  | (4,671,000 | )
Other income (expense) |  |  | (43,000 | ) |  |  | 251,000 |  |  |  | (52,000 | ) |  |  | (573,000 | ) |  |  | 336,000 |  |  |  | (949,000 | ) |  |  | (1,030,000 | )
Net income (loss) from operations before taxes |  |  | (313,000 | ) |  |  | (60,000 | ) |  |  | (123,000 | ) |  |  | (1,751,000 | ) |  |  | (1,851,000 | ) |  |  | (1,603,000 | ) |  |  | (5,701,000 | )
Nine Months Ended September 30, 2025 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 13,221,000 |  |  | $ | 37,000 |  |  | $ | - |  |  | $ | 32,000 |  |  | $ | 3,340,000 |  |  | $ | - |  |  | $ | 16,630,000 |
Cost of Revenue |  |  | 12,274,000 |  |  |  | 20,000 |  |  |  | (7,000 | ) |  |  | 36,000 |  |  |  | 4,430,000 |  |  |  | - |  |  |  | 16,753,000 |
Gross profit (loss) |  |  | 947,000 |  |  |  | 17,000 |  |  |  | 7,000 |  |  |  | (4,000 | ) |  |  | (1,090,000 | ) |  |  | - |  |  |  | (123,000 | )
Operating expense |  |  | 2,357,000 |  |  |  | 197,000 |  |  |  | (7,519,000 | ) |  |  | 3,124,000 |  |  |  | (855,000 | ) |  |  | 12,957,000 |  |  |  | 10,261,000 |
Operating income (loss) |  |  | (1,410,000 | ) |  |  | (180,000 | ) |  |  | 7,526,000 |  |  |  | (3,128,000 | ) |  |  | (235,000 | ) |  |  | (12,957,000 | ) |  |  | (10,384,000 | )
Other income (expense) |  |  | (110,000 | ) |  |  | (46,000 | ) |  |  | (22,000 | ) |  |  | 49,000 |  |  |  | (318,000 | ) |  |  | 677,000 |  |  |  | 230,000 |
Net income (loss) from operations |  |  | (1,520,000 | ) |  |  | (226,000 | ) |  |  | 7,504,000 |  |  |  | (3,079,000 | ) |  |  | (553,000 | ) |  |  | (12,280,000 | ) |  |  | (10,154,000 | )
Nine Months Ended September 30,2024 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 11,466,000 |  |  | $ | 192,000 |  |  | $ | 3,000 |  |  | $ | 2,000 |  |  | $ | 2,018,000 |  |  | $ | - |  |  | $ | 13,681,000 |
Cost of revenue |  |  | 10,715,000 |  |  |  | 719,000 |  |  |  | (2,000 | ) |  |  | 30,000 |  |  |  | 5,804,000 |  |  |  | - |  |  |  | 17,266,000 |
Gross profit (loss) |  |  | 751,000 |  |  |  | (527,000 | ) |  |  | 5,000 |  |  |  | (28,000 | ) |  |  | (3,786,000 | ) |  |  | - |  |  |  | (3,585,000 | )
Operating expense |  |  | 2,313,000 |  |  |  | 338,000 |  |  |  | 227,000 |  |  |  | 2,637,000 |  |  |  | 3,023,000 |  |  |  | 2,164,000 |  |  |  | 10,702,000 |
Operating income (loss) |  |  | (1,562,000 | ) |  |  | (865,000 | ) |  |  | (222,000 | ) |  |  | (2,665,000 | ) |  |  | (6,809,000 | ) |  |  | (2,164,000 | ) |  |  | (14,287,000 | )
Other income (expense) |  |  | (118,000 | ) |  |  | (73,000 | ) |  |  | 134,000 |  |  |  | (699,000 | ) |  |  | 52,000 |  |  |  | (934,000 | ) |  |  | (1,638,000 | )
Net loss from operations |  |  | (1,680,000 | ) |  |  | (938,000 | ) |  |  | (88,000 | ) |  |  | (3,364,000 | ) |  |  | (6,757,000 | ) |  |  | (3,098,000 | ) |  |  | (15,925,000 | )
Schedule of Disaggregation of Revenue | The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information:
Three months ended September 30, 2025 |  |  |
Packaging Printing and Fabrication |  | $ | 4,841,000 |
Commercial and Security Printing |  |  | 78,000 |
Real Property Rental Income |  |  | 16,000 |
Total Printed Products Revenue |  | $ | 4,935,000 |
Three months ended September 30, 2024 |  |  |
Packaging Printing and Fabrication |  | $ | 4,773,000 |
Commercial and Security Printing |  |  | 55,000 |
Real Property Rental Income |  |  | 18,000 |
Total Printed Products Revenue |  | $ | 4,846,000 |
Nine months ended September 30, 2025 |  |  |
Packaging Printing and Fabrication |  | $ | 12,839,000 |
Commercial and Security Printing |  |  | 334,000 |
Real Property Rental Income |  |  | 48,000 |
Total Printed Products Revenue |  | $ | 13,221,000 |
Nine months ended September 30, 2024 |  |  |
Packaging Printing and Fabrication |  | $ | 11,080,000 |
Commercial and Security Printing |  |  | 333,000 |
Real Property Rental Income |  |  | 53,000 |
Total Printed Products Revenue |  | $ | 11,466,000 |
Commercial Lending Revenue Information: |
Three months ended September 30, 2025 |  |  |
Net Investment Income |  | $ | 7,000 |
Total Commercial Lending Revenue |  | $ | 7,000 |
Three months ended September 30, 2024 |  |  |
Net Investment Income |  | $ | 45,000 |
Total Commercial Lending Revenue |  | $ | 45,000 |
Nine months ended September 30, 2025 |  |  |
Net investment income |  | $ | 37,000 |
Total Commercial Lending Revenue |  | $ | 37,000 |
Nine months ended September 30, 2024 |  |  |
Net Investment Income |  | $ | 192,000 |
Total Commercial Lending Revenue |  | $ | 192,000 |
Nine months ended September 30, 2024 |  |  |
Retail sales |  | $ | 3,000 |
Total Direct Marketing Revenue |  | $ | 3,000 |
Biotechnology Revenue Information: |  |  |
Three months ended September 30, 2025 |  |  |
Retail internet sales |  | $ | 11,000 |
Total Biotechnology Revenue |  | $ | 11,000 |
Three months ended September 30, 2024 |  |  |
Retail internet sales |  | $ | 1,000 |
Total Biotechnology Revenue |  | $ | 1,000 |
Nine months ended September 30, 2025 |  |  |
Retail internet sales |  | $ | 32,000 |
Total Biotechnology Revenue |  | $ | 32,000 |
Nine months ended September 30, 2024 |  |  |
Retail internet sales |  | $ | 2,000 |
Total Biotechnology Revenue |  | $ | 2,000 |
Securities Revenue Information: |
Three months ended September 30, 2025 |  |  |
Rental income |  | $ | 702,000 |
Commission income |  | $ | 737,000 |
Total Securities Revenue |  | $ | 1,439,000 |
Three months ended September 30, 2024 |  |  |
Rental income |  | $ | 478,000 |
Commission income |  | $ | 229,000 |
Total Securities Revenue |  | $ | 707,000 |
Nine months ended September 30, 2025 |  |  |
Rental income |  | $ | 2,099,000 |
Commission income |  | $ | 1,241,000 |
Total Securities Revenue |  | $ | 3,340,000 |
Nine months ended September 30, 2024 |  |  |
Rental income |  | $ | 1,281,000 |
Commission income |  | $ | 737,000 |
Total Securities Revenue |  | $ | 2,018,000 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration